人福医药(600079)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

600079 人福医药

已收盘 12-24 15:00:00

{"stockData":{"symbol":"600079","market":"SH","secType":"STK","nameCN":"人福医药","latestPrice":24.03,"timestamp":1735023601000,"preClose":23.53,"halted":0,"volume":12099157,"delay":0,"floatShares":1543000000,"shares":1632000000,"eps":1.1981,"marketStatus":"已收盘","marketStatusCode":5,"change":0.5,"latestTime":"12-24 15:00:00","open":23.5,"high":24.05,"low":23.37,"amount":288000000,"amplitude":0.0289,"askPrice":24.03,"askSize":288,"bidPrice":24.02,"bidSize":40,"shortable":0,"etf":0,"ttmEps":1.1981,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1735090200000},"adr":0,"adjPreClose":23.53,"symbolType":"stock","openAndCloseTimeList":[[1735003800000,1735011000000],[1735016400000,1735023600000]],"highLimit":25.88,"lowLimit":21.18,"ibTradeSell":false,"ibTradeBuySell":true,"totalEquity":1632225965,"pbRate":2.2,"roa":"--","roe":"9.02%","epsLYR":1.32,"committee":-0.081081,"marketValue":39222000000,"floatMarketCap":37083000000,"peRate":20.056757,"changeRate":0.0212,"turnoverRate":0.0078,"status":0,"nextConnectDate":"根据港交所公布的数据，今日已停止北向交易，下一个交易日为北京时间 2024-12-27。"},"requestUrl":"/m/hq/s/600079/wiki","defaultTab":"wiki","newsList":[{"id":"2493784539","title":"人福医药12月23日主力净流出5362万元 散户资金买入","url":"https://stock-news.laohu8.com/highlight/detail?id=2493784539","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2493784539?lang=zh_cn&edition=full","pubTime":"2024-12-23 15:18","pubTimestamp":1734938291,"startTime":"0","endTime":"0","summary":"12月23日, 人福医药股价跌2.08%，报收23.53元，成交金额4.45亿元，换手率1.22%，振幅2.58%，量比1.23。人福医药今日主力资金净流出5362万元，上一交易日主力净流入2609万元。该股近5个交易日下跌2.57%，主力资金累计净流出1.02亿元，其中1个交易日为股价上涨时净流出；近20日主力资金累计净流入9012万元，其中净流入天数为11日。该股主力净额占比0.15%，A股市场排名3325/5000，低于行业平均值。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241223152116a204078a&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241223152116a204078a&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK0096","BK0070","BK0012","BK0188","600079","BK0185","BK0028","BK0239"],"gpt_icon":0},{"id":"2492964148","title":"人福医药易主：宜昌国资增持背后，麻醉巨头困境浮现","url":"https://stock-news.laohu8.com/highlight/detail?id=2492964148","media":"观察者网","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2492964148?lang=zh_cn&edition=full","pubTime":"2024-12-17 22:53","pubTimestamp":1734447212,"startTime":"0","endTime":"0","summary":"在此困境下，宜昌国资的增持无疑为公司带来了一丝曙光。然而，人福医药的危机并未完全解除。至此，宜昌产投集团合计控制人福医药表决权比例已达12.35%。截图来自人福医药公告值得注意的是，这并非宜昌国资首次增持人福医药的股份。有分析人士指出，尽管宜昌国资的增持有助于稳定人福医药的股价和市场信心，但能否真正带领人福医药走出困境并实现长远发展仍是一个未知数。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241217225459984c90d0&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241217225459984c90d0&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK0070","BK0239","BK0028","BK0012","BK0188","600079","BK0185","BK0096"],"gpt_icon":0},{"id":"2492939644","title":"人福医药12月17日遭主力抛售2828万元 环比增加266.32%","url":"https://stock-news.laohu8.com/highlight/detail?id=2492939644","media":"市场透视","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2492939644?lang=zh_cn&edition=full","pubTime":"2024-12-17 15:21","pubTimestamp":1734420086,"startTime":"0","endTime":"0","summary":"12月17日, 人福医药股价跌0.54%，报收24.02元，成交金额4.27亿元，换手率1.16%，振幅2.28%，量比0.68。人福医药今日主力资金净流出2828万元，上一交易日主力净流出772万元，今日环比增加266.32%。该股近5个交易日下跌0.41%，主力资金累计净流入5850万元；近20日主力资金累计净流入1.85亿元，其中净流入天数为12日。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241217154832ab7e823d&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241217154832ab7e823d&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["600079","BK0012","BK0070","BK0188","BK0185","BK0096","BK0028","BK0239"],"gpt_icon":0},{"id":"2492672370","title":"人福医药易主在即 宜昌国资出手控股增至12.35%","url":"https://stock-news.laohu8.com/highlight/detail?id=2492672370","media":"长江商报","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2492672370?lang=zh_cn&edition=full","pubTime":"2024-12-17 08:59","pubTimestamp":1734397142,"startTime":"0","endTime":"0","summary":"公告披露，宜昌产投集团注册资本为100亿元，宜昌市国资委持有其100%股权。根据公告，当代科技持有人福医药约3.87亿股股份，持股及对应表决权比例为23.7%，目前已全部被司法冻结及轮候冻结。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241217090646ab7dadf9&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241217090646ab7dadf9&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["600079","BK0012","BK0096","BK0185","BK0028","BK0239","BK0070","BK0188"],"gpt_icon":0},{"id":"2491704073","title":"宜昌国资再次拿下人福医药3.67%的表决权，合计表决权增至12.35%","url":"https://stock-news.laohu8.com/highlight/detail?id=2491704073","media":"项乾","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2491704073?lang=zh_cn&edition=full","pubTime":"2024-12-13 23:29","pubTimestamp":1734103747,"startTime":"0","endTime":"0","summary":"项干消息：刚刚拿下人福医药8.69%股份表决权不久，宜昌产投集团再度拿下3.67%的股份表决权。至此，宜昌产投合计控制人福医药表决权比例达12.35%。因此，本次权益变动后，宜昌产投集团合计控制公司201,597,643股股份所对应的表决权，占公司有表决权股份总数的12.35%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241213233553ab75ab22&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241213233553ab75ab22&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK0012","BK0096","BK0028","BK0185","600079","BK0188","BK0070","BK0239"],"gpt_icon":0},{"id":"2491342931","title":"大股东太“坑人” 连续三年突击分红输血 人福医药或被“国家队”收编","url":"https://stock-news.laohu8.com/highlight/detail?id=2491342931","media":"海闻社","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2491342931?lang=zh_cn&edition=full","pubTime":"2024-12-13 17:09","pubTimestamp":1734080977,"startTime":"0","endTime":"0","summary":"人福医药持有宜昌人福80%股权，剩余20%股权由国药股份持有。在披露2024年半年度财报的同一时刻，人福医药同步披露了4项关联交易。今年5月，人福医药发布公告，当代科技因违规减持遭上交所监管警示。今年10月22日，人福医药及控股股东当代科技因涉嫌信息披露违法违规，被中国证监会立案调查。根据公司年报，2023年，人福医药员工薪酬31.8亿元，同比增长18%。基本上，人福医药成为国资，被国家队收编，已经是定局。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241213175102a1eb9e0a&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241213175102a1eb9e0a&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK0012","BK0096","BK0028","BK0185","600079","BK0188","BK0070","BK0239"],"gpt_icon":0},{"id":"2490804098","title":"人福医药(600079.SH)：依托咪酯中/长链脂肪乳注射液获药品注册证书","url":"https://stock-news.laohu8.com/highlight/detail?id=2490804098","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2490804098?lang=zh_cn&edition=full","pubTime":"2024-12-12 20:00","pubTimestamp":1734004821,"startTime":"0","endTime":"0","summary":"智通财经APP讯，人福医药(600079.SH)发布公告，公司控股子公司宜昌人福药业有限责任公司近日收到国家药品监督管理局核准签发的依托咪酯中/长链脂肪乳注射液的《药品注册证书》。依托咪酯中/长链脂肪乳注射液是一种非巴比妥类催眠性静脉麻醉药，可用于成人、6个月以上婴幼儿、儿童和青少年的全身麻醉诱导。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1224215.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0239","BK0188","BK0012","BK0185","BK0096","600079","BK0070","BK0028"],"gpt_icon":0},{"id":"2490356388","title":"人福医药：产品取得注册证","url":"https://stock-news.laohu8.com/highlight/detail?id=2490356388","media":"每日经济新闻","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2490356388?lang=zh_cn&edition=full","pubTime":"2024-12-12 19:27","pubTimestamp":1734002863,"startTime":"0","endTime":"0","summary":"每经AI快讯，人福医药 12月12日晚间发布公告称，人福医药集团股份公司控股子公司宜昌人福药业有限责任公司近日收到国家药品监督管理局核准签发的依托咪酯中/长链脂肪乳注射液的《药品注册证书》。产品名称为“依托咪酯中/长链脂肪乳注射液”。2023年1至12月份，人福医药的营业收入构成为：医药占比53.05%，医药批发及相关业占比46.05%。截至发稿，人福医药市值为412亿元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241212192815a1e8f0bc&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241212192815a1e8f0bc&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK0185","600079","BK0188","BK0070","BK0012","BK0239","BK0028","BK0096"],"gpt_icon":0},{"id":"2490388358","title":"人福医药：宜昌产投集团合计控制公司12.35%表决权股份","url":"https://stock-news.laohu8.com/highlight/detail?id=2490388358","media":"格隆汇资讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2490388358?lang=zh_cn&edition=full","pubTime":"2024-12-12 19:22","pubTimestamp":1734002561,"startTime":"0","endTime":"0","summary":"宜昌产投集团通过芜湖信福股权投资合伙企业间接持有公司59,829,636股股份所对应的表决权，占公司有表决权股份总数的3.67%。本次权益变动后，宜昌产投集团合计控制公司201,597,643股股份所对应的表决权，占公司有表决权股份总数的12.35%，不触及要约收购。本次权益变动不会导致公司控股股东及实际控制人发生变化。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241212192248ab72462b&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241212192248ab72462b&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK0188","BK0096","600079","BK0185","BK0239","BK0070","BK0028","BK0012"],"gpt_icon":0},{"id":"2490780941","title":"人福医药最新公告：控股子公司宜昌人福依托咪酯中/长链脂肪乳注射液获药品注册证书","url":"https://stock-news.laohu8.com/highlight/detail?id=2490780941","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2490780941?lang=zh_cn&edition=full","pubTime":"2024-12-12 19:20","pubTimestamp":1734002441,"startTime":"0","endTime":"0","summary":"人福医药公告，公司控股子公司宜昌人福近日收到国家药品监督管理局核准签发的依托咪酯中/长链脂肪乳注射液的《药品注册证书》。该药品主要用于成人、6个月以上婴幼儿、儿童和青少年的全身麻醉诱导。本次获批标志着宜昌人福具备了在国内市场销售该药品的资格，进一步丰富了公司在麻醉领域的产品管线。该项目累计研发投入约为2600万元。2023年度依托咪酯注射剂型全国销售额约为11.65亿元。宜昌人福将根据市场需求安排该药品的生产上市。以上内容为证券之星据公开信息整理，由智能算法生成，不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024121200031912.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0185","BK0188","600079","BK0096","BK0070","BK0239","BK0028","BK0012"],"gpt_icon":0},{"id":"2490822868","title":"人福医药12月11日主力净流入5624万元 散户资金抛售","url":"https://stock-news.laohu8.com/highlight/detail?id=2490822868","media":"市场透视","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2490822868?lang=zh_cn&edition=full","pubTime":"2024-12-11 15:17","pubTimestamp":1733901463,"startTime":"0","endTime":"0","summary":"12月11日, 人福医药股价涨4.56%，报收25.22元，成交金额10.01亿元，换手率2.59%，振幅7.05%，量比2.13。人福医药今日主力资金净流入5624万元，上一交易日主力净流入1963万元，今日环比增加186.50%。该股近5个交易日上涨7.87%，主力资金累计净流入1.14亿元，其中1个交易日为股价下跌时净流入；近20日主力资金累计净流入2.28亿元，其中净流入天数为13日。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241211151941a1e578f7&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241211151941a1e578f7&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK0028","BK0096","BK0188","BK0070","BK0012","BK0239","BK0185","600079"],"gpt_icon":0},{"id":"2490888301","title":"人福医药创近11月新高 18家券商看好","url":"https://stock-news.laohu8.com/highlight/detail?id=2490888301","media":"智选洞察","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2490888301?lang=zh_cn&edition=full","pubTime":"2024-12-11 11:23","pubTimestamp":1733887395,"startTime":"0","endTime":"0","summary":"12月11日，人福医药股价大幅上涨，截至11点23分，人福医药上涨5.10%，报25.35元/股，创近11个月新高，成交5.78亿元，换手率1.51%，振幅6.01%。此外，数据统计显示，近半年内1家券商给予增持建议，17家券商给予买入建议。资金动向截止发稿，人福医药获得主力净流入3779万元，其中超大单流入2885万元，大单流入893万元。最新财报显示，今年三季报，人福医药实现营业收入191.43亿元，同比增长5.70%，净利润为15.90亿元，同比减少10.12%，基本每股收益为0.98元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241211112330a1e50190&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241211112330a1e50190&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK0012","BK0096","BK0028","BK0185","600079","BK0188","BK0070","BK0239"],"gpt_icon":0},{"id":"2490660070","title":"人福医药(600079.SH)董事王学海累计减持89万股 减持期满","url":"https://stock-news.laohu8.com/highlight/detail?id=2490660070","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2490660070?lang=zh_cn&edition=full","pubTime":"2024-12-10 16:10","pubTimestamp":1733818258,"startTime":"0","endTime":"0","summary":"智通财经APP讯，人福医药(600079.SH)发布公告，截至本公告披露之日，本次减持计划的减持时间区间届满，董事王学海累计减持公司股份89万股，占公司总股本的比例为0.05%。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1222692.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0096","BK0012","BK0185","BK0239","BK0028","BK0188","BK0070","600079"],"gpt_icon":0},{"id":"2489286330","title":"人福医药控股股东4.57亿股解除冻结","url":"https://stock-news.laohu8.com/highlight/detail?id=2489286330","media":"财中社","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2489286330?lang=zh_cn&edition=full","pubTime":"2024-12-06 16:45","pubTimestamp":1733474700,"startTime":"0","endTime":"0","summary":"财中社12月6日电人福医药（600079）发布关于控股股东持有股份被解除冻结的公告。控股股东武汉当代科技产业集团股份有限公司目前持有公司股份总数为3.87亿股，占公司总股本的23.70%。截至公告披露之日，当代科技所持股份已全部被司法标记及轮候冻结，占其所持股份总数的100%。此次解除冻结的股份为4.57亿股，解除冻结时间为2024年12月5日。上述股份与上海富金通商业保理有限公司的保理合同纠纷而被冻结，冻结时占当时公司总股本的27.98%。2024年前三季度，人福医药实现收入191.43亿元，归母净利润15.90亿元。（文章来源：财中社）","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241206164755ab621825&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241206164755ab621825&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["600079","BK0239","BK0028","BK0096","BK0070","BK0012","BK0185","BK0188"],"gpt_icon":0},{"id":"2489408925","title":"人福医药最新公告：控股股东所持公司4.57亿股股份被解除冻结","url":"https://stock-news.laohu8.com/highlight/detail?id=2489408925","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2489408925?lang=zh_cn&edition=full","pubTime":"2024-12-06 16:12","pubTimestamp":1733472779,"startTime":"0","endTime":"0","summary":"人福医药公告称，公司控股股东当代科技所持公司4.57亿股股份被上海市黄埔区人民法院解除轮候冻结，占其所持股份比例100%，占当时公司总股本比例27.98%，解除冻结时间为2024年12月5日。以上内容为证券之星据公开信息整理，由智能算法生成，不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024120600026387.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0096","BK0028","BK0070","600079","BK0185","BK0188","BK0239","BK0012"],"gpt_icon":0},{"id":"2489482622","title":"人福医药最新公告：熊去氧胆酸胶囊获得药品注册证书","url":"https://stock-news.laohu8.com/highlight/detail?id=2489482622","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2489482622?lang=zh_cn&edition=full","pubTime":"2024-12-05 16:50","pubTimestamp":1733388622,"startTime":"0","endTime":"0","summary":"人福医药公告，控股子公司宜昌人福近日收到国家药品监督管理局核准签发的熊去氧胆酸胶囊的《药品注册证书》。该药品主要用于治疗胆囊胆固醇结石、胆汁淤积性肝病和胆汁反流性胃炎。截至目前，该项目累计研发投入约为2000万元人民币。以上内容为证券之星据公开信息整理，由智能算法生成，不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024120500027552.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0188","BK0012","BK0185","BK0070","BK0096","600079","BK0028"],"gpt_icon":0},{"id":"2489484901","title":"人福医药(600079.SH)：熊去氧胆酸胶囊获药品注册证书","url":"https://stock-news.laohu8.com/highlight/detail?id=2489484901","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2489484901?lang=zh_cn&edition=full","pubTime":"2024-12-05 16:38","pubTimestamp":1733387922,"startTime":"0","endTime":"0","summary":"智通财经APP讯，人福医药(600079.SH)发布公告，公司控股子公司宜昌人福药业有限责任公司(简称“宜昌人福”，公司持有其80%的股权)近日收到国家药品监督管理局核准签发的熊去氧胆酸胶囊的《药品注册证书》。本次熊去氧胆酸胶囊获批适应症为：(1)胆囊胆固醇结石——必须是X射线能穿透的结石，同时胆囊收缩功能须正常;(2)胆汁淤积性肝病(如：原发性胆汁性肝硬化);(3)胆汁反流性胃炎。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1220816.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0012","BK0028","BK0070","BK0185","BK0239","600079","BK0096","BK0188"],"gpt_icon":0},{"id":"2488160148","title":"人福医药子公司新药上市申请获受理 研发投入1.6亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=2488160148","media":"中新经纬","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2488160148?lang=zh_cn&edition=full","pubTime":"2024-12-04 17:52","pubTimestamp":1733305976,"startTime":"0","endTime":"0","summary":"截至目前，光谷人福就该项目累计研发投入约为1.6亿元。人福医药称，目前中国尚无同类型产品上市。除了人福医药上市申请获得受理外，2024年7月，北京诺思兰德生物技术股份有限公司宣布，其治疗用生物制品1类新药塞多明基注射液上市申请获国家药品监督管理局受理，适应症为严重下肢缺血性疾病导致的肢体溃疡。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241204201908a26c1bb3&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241204201908a26c1bb3&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK0188","BK0096","600079","BK0185","BK0239","BK0070","BK0028","BK0012"],"gpt_icon":0},{"id":"2488515681","title":"人福医药(600079.SH)子公司重组质粒-肝细胞生长因子注射液上市许可申请获受理","url":"https://stock-news.laohu8.com/highlight/detail?id=2488515681","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2488515681?lang=zh_cn&edition=full","pubTime":"2024-12-04 16:50","pubTimestamp":1733302228,"startTime":"0","endTime":"0","summary":"智通财经APP讯，人福医药 发布公告，公司控股子公司武汉光谷人福生物医药有限公司近日收到国家药品监督管理局核准签发的重组质粒-肝细胞生长因子注射液药品注册上市许可申请《受理通知书》。重组质粒-肝细胞生长因子注射液药品注册上市许可申请被国家药品监督管理局受理，标志着该品种境内生产药品注册工作进入了审评阶段，公司将积极推进后续相关工作，如顺利通过审评审批，将丰富公司的产品线，有利于提升公司的市场竞争力。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1220251.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["600079","BK0239","BK0028","BK0096","BK0070","BK0012","BK0185","BK0188"],"gpt_icon":0},{"id":"2488514701","title":"人福医药最新公告：子公司药品上市许可申请获受理","url":"https://stock-news.laohu8.com/highlight/detail?id=2488514701","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2488514701?lang=zh_cn&edition=full","pubTime":"2024-12-04 16:50","pubTimestamp":1733302218,"startTime":"0","endTime":"0","summary":"人福医药公告，公司控股子公司光谷人福近日收到国家药品监督管理局核准签发的重组质粒-肝细胞生长因子注射液药品注册上市许可申请《受理通知书》。该药品适用于治疗严重下肢缺血性疾病导致的肢体静息痛，为治疗用生物制品1类新药，目前国内尚无同类型产品上市。光谷人福该项目累计研发投入约为人民币1.6亿元。该药品注册上市许可申请被受理，标志着该品种境内生产药品注册工作进入了审评阶段，公司将积极推进后续相关工作。以上内容为证券之星据公开信息整理，由智能算法生成，不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024120400028919.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["600079","BK0239","BK0028","BK0096","BK0070","BK0012","BK0185","BK0188"],"gpt_icon":0}],"profile":{"ret":0,"listingDate":"1997-06-06","address":"湖北省武汉市洪山区东湖高新区高新大道666号","stockEarnings":[{"period":"1week","weight":0.0004},{"period":"1month","weight":0.0685},{"period":"3month","weight":0.3426},{"period":"6month","weight":0.4033},{"period":"1year","weight":-0.0315},{"period":"ytd","weight":-0.0007}],"companyName":"人福医药集团股份公司","boardCode":"AI0027","perCapita":"36888股","boardName":"医药制造业","registeredCapital":"163222万元","compareEarnings":[{"period":"1week","weight":0.0095},{"period":"1month","weight":0.0387},{"period":"3month","weight":0.1717},{"period":"6month","weight":0.152},{"period":"1year","weight":0.1626},{"period":"ytd","weight":0.1407}],"survey":"　　人福医药集团股份公司的主营业务为药品的研发、生产和销售。公司主要产品为药品、医疗器械。公司是湖北省医药工业龙头企业和国家技术创新示范企业。公司连续14年入选国家工信部“中国医药工业百强榜”，入选“2023中国制造业企业500强”、“2023中国制造业民营企业500强”榜单。","serverTime":1735066479642,"listedPrice":5.22,"stockholders":"41834人(较上一季度减少11.45%)","compareStock":{"symbol":"000001.SH","name":"上证指数"}},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.29.3","shortVersion":"4.29.3","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"人福医药(600079)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供人福医药(600079)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"人福医药,600079,人福医药股票,人福医药股票老虎,人福医药股票老虎国际,人福医药行情,人福医药股票行情,人福医药股价,人福医药股市,人福医药股票价格,人福医药股票交易,人福医药股票购买,人福医药股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"人福医药(600079)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供人福医药(600079)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}